Mifepristone ruling leaves mail and teleprescribing intact
Supreme Court pauses mifepristone limits, preserving mail & telehealth access during legal challenge. Temporary certainty for providers & pharmacies.
15 May 2026
FDA Approves Flavored Vaping Products Amid Pressure
The FDA authorized new flavored vaping products for the first time, approving mango, blueberry, and menthol e-cigarettes from manufacturer Glas.
05 May 2026
Artificial Sweeteners Linked to Cognitive Decline
Artificial sweeteners may be linked to cognitive decline, raising questions about their long-term health implications despite prior regulatory approvals.
05 May 2026
Supreme Court Freezes Mifepristone Mailing Restrictions
Mifepristone remains accessible as the Supreme Court reviews appeals against a ruling that sought to limit its distribution.
04 May 2026
White House Fast-Tracks Psychedelic Mental Health Therapies
FDA review for psychedelic therapies fast-tracked by executive order. Expands research, patient access for mental health, and prepares for drug rescheduling.
04 May 2026
Estrogen Patch Demand Surge Creates Supply Crunch, With Shortages Likely to Persist
Estrogen patch demand surges after FDA warning removals, causing a 3-year supply shortage that impacts menopause treatment access.
03 May 2026
FDA Report Upholds Infant Formula Safety in the U.S.
A major federal study has affirmed U.S. infant formula safety, finding the vast majority of products contain low or undetectable levels of common contaminants.
29 Apr 2026
Trump Signs Executive Order to Fast-Track Psychedelic Research for Veteran Mental Health
Trump order accelerates psychedelic research, including $50 million for ibogaine studies, with veterans’ mental health highlighted on April 18.
19 Apr 2026
